BiolActis is dedicated to developing innovative biologics that will treat metabolic disorders. The company's R&D program aims to support excellent science with an ultimate view of improving healthcare. The program includes Clinical Trials which add significantly to our understanding of biological effects and behavioral mechanisms of MPMs. In the first phase, we conduct lengthy preclinical testing in order to confirm that MPMs have the anticipated safety profile before launching Clinical Trials thus limiting and mitigating the risks and costs of human testing. BiolActis also does extensive formulation work to produce a product that can be delivered to humans in different forms (capsules, powders, drinks, food and cream) in order to ensure compliance. The company carries out a series of Clinical Trials in human carefully supervised, approved by Regulatory Authorities and Ethics Committees, to evaluate each MPM, to determine how it acts and whether it is safe and effective in the target human population.
